Osimertinib, a pioneering third-generation EGFR-TKI, emerged as a response to the T790M mutation in patients who developed resistance to the earlier TKIs, providing a lifeline for those battling advanced NSCLC (25, 27). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.